TABLE 2.
Time to selection of phenotypic resistance to APV and EFV using WT versus M184V subtype B and C isolatesa
| Virus | Drug | Primary/major resistance mutation | Time to first appearance of primary resistance mutation (weeks) |
|---|---|---|---|
| B-WT (n = 5) | EFV | K103N | 22.0 ± 2.0 |
| B-M184V (n = 2) | EFV | K103N, M184V | 32.5 ± 2.5b |
| C-WT (n = 5) | EFV | V106M | 13.6 ± 1.6 |
| C-M184V (n = 2) | EFV | V106M, M184V | 24 ± 1.0b |
| B-WT (n = 2) | APV | I54M/L | 24.5 ± 1.5 |
| B-M184V (n = 2) | APV | I54L/V, M184V | 53.5 ± 5.2b |
a
APV and EFV concentrations were increased in stepwise progression based on RT activities. Genotypic analysis was performed to monitor the time to first appearance of major/primary resistance mutations associated with high-level phenotypic resistance (see Tables 1 and 3). Values represent the mean ± standard error of the mean of experiments performed on different clinical isolates.
b
P < 0.05 for t tests of WT versus M184V isolates.